Infectious diseases screening panel
Syndromic screening of HIV, Hepatitis B and Hepatitis C
The growing challenges of pandemic risk management for infectious diseases drives the need for decentralized diagnostic solutions. Most available diagnostic solutions are focussing on detecting a single parameter. However, the Center for Disease Control and Prevention (CDC) estimates that about 10% of people in the United States infected with HIV are co-infected with Hepatitis B. More than 120 million high-risk populations need to be screened on a infectious disease panel in western countries alone. That is why the HAS and the WHO are both looking for assays providing full serological status on the three mains sexually transmitted diseases HIV, HCV and HBV.
Using a single drop of blood, the MagIA diagnostics Infectious diseases panel detects the pathogens that most commonly present a co-infection: Hepatitis B, Hepatitis C and HIV.
The rapid and accurate knowledge of the presence or absence of the related pathogens will help make timely decisions about treatment, vaccination, infection control, and patient return to work and family.